Pyramid Labs Appoints Dirk Lange as CEO and Announces a Doubling of Commercial Fill-Finish Capacity
06 Mar 2024
Executive ChangeAcquisition
COSTA MESA, Calif.--(BUSINESS WIRE)--Pyramid Labs, Inc. (“Pyramid” or the “Company”), a leader in drug product contract development and manufacturing with expertise in proteins, oligos, and peptides, announced today the appointment of Dirk Lange as Chief Executive Officer. Medhat Gorgy, who founded Pyramid in 1988 and has led the Company’s growth and evolution over its 36-year history, will continue to support the business as the Company’s chairman.
'We are seeing increased demand for our DP development and manufacturing services across biologics, small molecules and specifically novel modalities such as oligo nucleotides, where Pyramid offers differentiated capabilities and years of experience'
“I am excited to lead Pyramid during this pivotal time in the Company’s growth trajectory and as the company is doubling its commercial fill-finish capacity,” noted Dirk Lange. “It’s a critical time for clients to secure their drug product supply chain and we are building on a 36-year track record defined by quality, reliability and innovation. Pyramid’s relentless focus on integrity and performance created outstanding service levels and enabled dozens of clients to realize their vision and bring products into the clinic and to the market.”
Lange brings a wealth of knowledge and expertise in building and leading global teams in the CDMO sector and providing best-in-class services to their client bases. Lange most recently led MilliporeSigma’s Life Science Services business and previously was the CEO of KBI Biopharma and Selexis. He joins Pyramid at a point of accelerated growth, as the company is doubling its commercial fill-finish capacity.
“We are seeing increased demand for our DP development and manufacturing services across biologics, small molecules and specifically novel modalities such as oligo nucleotides, where Pyramid offers differentiated capabilities and years of experience,” Lange added.
Mr. Gorgy founded Pyramid Labs in 1988 and scaled the Company into a leader in formulation development, lyophilization, aseptic fill-finish of biologics, and analytical services for the pharmaceutical and biotech industry. He has spearheaded Pyramid’s development of its best-in-class reputation for quality, technical expertise, and customer service throughout the past 36 years, and will continue to support the Company as its Chairman.
“We are very pleased to welcome Dirk to the Pyramid team as we continue in our transformative growth phase,” commented Medhat Gorgy. “Pyramid will benefit from his vast experience in the pharmaceutical industry and depth of knowledge in this sector, and I look forward to supporting him in my new role as Chairman.”
“We are grateful for Medhat’s leadership over Pyramid’s long-tenured history; he stewarded the Company through a period of extraordinary growth, built an exceptional quality- and service-oriented organization, and positioned Pyramid for sustained future success,” said Audax Private Equity Partner Keith Palumbo and Managing Director Steve Weaver. “Dirk brings proven experience and strategic leadership to help Pyramid continue its momentum and accelerate its growth in this next chapter for the Company.”
Since Audax Private Equity’s investment in 2023, Pyramid has invested substantially in expanding its capacity to better service its clients, including a facility expansion to double vial-filling and syringe filling capacity.
ABOUT PYRAMID LABS
Pyramid Labs, Inc. (“Pyramid”) is a California-based CDMO focused on formulation development, analytical and stability testing, and aseptic fill-finish manufacturing for clinical and commercial stage programs. Founded in 1988 and headquartered in Orange County, California, Pyramid operates three manufacturing facilities that allow the Company to offer its pharmaceutical and biotech customers a wide range of services, ranging from preclinical development to scale up aseptic fill-finish commercial manufacturing, storage and distribution.
Learn more at PyramidLabs.com or via email at info@pyramidlabs.com.
ABOUT AUDAX PRIVATE EQUITY
Based in Boston and San Francisco, Audax Private Equity is a leading capital partner for middle and lower middle market companies that seeks to facilitate transformational growth. With approximately $19 billion of assets under management, over 250 employees, and 100-plus investment professionals, the firm has invested in more than 170 platforms and 1,250 add-on acquisitions since its founding in 1999. Through our disciplined Buy & Build approach, across six core industry verticals, Audax helps portfolio companies execute organic and inorganic growth initiatives that fuel revenue expansion, optimize operations, and significantly increase equity value. For more information, visit www.audaxprivateequity.com or follow us on LinkedIn.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
-Targets
-Drugs
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.